# Study of TAVO103A in Healthy Volunteers

> **NCT05313152** · PHASE1 · COMPLETED · sponsor: **Tavotek Biotherapeutics** · enrollment: 30 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** TAVO103A
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05313152
- **Lead sponsor:** Tavotek Biotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-05
- **Primary completion:** 2023-04-26
- **Final completion:** 2023-06-08
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05313152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05313152, "Study of TAVO103A in Healthy Volunteers". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT05313152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*